Beyond Air Inc.

  • Home
  • About Us
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • PPHN
    • Viral Lung Infections
    • Nontuberculous Mycobacteria (NTM)
    • Solid Tumors
  • News & Events
    • Press Releases
    • Presentations
    • Publications
    • Events
    • Email Alerts
  • Investors
    • Overview
    • Company Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar

Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021

Jun 10, 2021 4:05pm EDT

Beyond Air® Reaches Settlement Agreement with Circassia for LungFit® PH

May 26, 2021 7:30am EDT

Beyond Air® Schedules Fiscal Year 2021 Financial Results Conference Call and Webcast

May 25, 2021 7:30am EDT

Beyond Air® Strengthens Commercial Leadership Team with Appointments of Head of Sales and Head of Marketing

May 20, 2021 8:00am EDT

Beyond Air® Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit® PRO Programs at ATS 2021

May 13, 2021 8:00am EDT

Beyond Air® Appoints Peter Senior as Director of Business Development

May 03, 2021 8:00am EDT

Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in May 2021

Apr 14, 2021 8:00am EDT

Beyond Air® to Present Abstracts at the American Thoracic Society Virtual Sessions in May 2021

Mar 24, 2021 8:00am EDT

Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in March 2021

Mar 01, 2021 8:00am EST

Beyond Air® Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease

Feb 16, 2021 8:00am EST
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...17
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    Important Safety Information

    †Caution - LungFit is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.

    © 2022 Beyond Air Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Search